In 1959, as the Cold War hardened, 10 million Soviet children received an oral polio vaccine developed by Albert Sabin in the United States. The Soviet trials helped prove it safe and effective. Science crossed the Iron Curtain because polio did not care which side of it a child lived on.
Sixty-seven years later, medicine is meeting new checkpoints.
Washington is reading clinical trials in China as a national-security question. Britain is treating drug pricing as an industrial-policy problem. Brussels is being asked to make patient access a budget test. Medicare is using a temporary side door to cover obesity treatment.
Medicine is no longer only crossing borders. Borders are being written into medicine.
- The Trial Has a Passport Now. U.S. lawmakers are investigating clinical-trial activity in China by five major drugmakers, including work involving Xinjiang and military-linked hospitals. The protocol is now being read as a security document.
- The World’s Lowest Price Has a Catch. Seventeen major drugmakers have signed most-favoured-nation pricing deals. Smaller companies appear much less convinced.
- Britain Cut the Bill. The Access Tab Is Still Open. The UK has lowered its statutory payment rate for newer branded medicines. That may calm industry. It does not automatically get medicines to patients faster.
- GLP-1s Just Took the Side Door to Medicare. Eligible beneficiaries can access certain GLP-1 medicines through a temporary CMS demonstration outside the ordinary Part D payment flow.
- COVID’s Emergency Exit Is Open. America is winding down the emergency-use-authorisation declarations that defined the pandemic era. The ordinary system is back on the clock.
- The Cure Just Got a Bodyguard. FDA has approved a donor immune-cell therapy designed not only to fight blood cancer, but also to reduce the harm caused by transplantation itself.
- The Resistance Crisis Is Growing in the Dark. WHO says fungal disease and antifungal resistance remain underdiagnosed, under-resourced and largely absent from the systems meant to protect public health.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
The Trial Has a Passport Now
Washington is no longer treating clinical-trial geography as a back-office detail.
The U.S. House Select Committee on China has asked Eli Lilly, Merck, AbbVie, Pfizer and Bristol Myers Squibb for information on clinical-trial activity in China, including work involving Xinjiang and military-affiliated hospitals.
The requests cover site selection, good-clinical-practice safeguards, due diligence, data protection and biotechnology partnerships. The committee explicitly says it has not established illegal wrongdoing by the companies. Merck, AbbVie, Eli Lilly, Pfizer, Bristol Myers Squibb, Reuters reporting.
That distinction matters. This is an investigation, not a verdict. But the political signal is unmistakable: trial sites, patient data and research partnerships are now being assessed through the lens of national security. A clinical trial is supposed to produce evidence. It is increasingly being judged as a security relationship.
IPM latest
Europe’s Budget Needs a Patient Access Test
As Ireland begins its Presidency of the Council of the European Union, IPM Alliance is making a direct call: Europe’s next Multiannual Financial Framework must face a patient access test. Irish Presidency programme | European Commission: EU budget 2028 to 2034.
In meetings across Brussels, Denis Horgan has urged policymakers to fund discovery, finance delivery and judge health investment by a tougher question: does it reach patients? Europe is already framing its next long-term budget around competitiveness, biotech, AI, health data, resilience and strategic autonomy. But innovation that does not reach patients is not competitiveness. It is unfinished policy.
For personalised medicine, access starts before the prescription: with the diagnostic test, the biomarker, genomic infrastructure, data systems, clinical pathways and the workforce able to use them.
No test, no treatment. No data, no evidence.
No infrastructure, no access.
The next MFF must do more than support research. It must finance the missing middle: diagnostics, genomics, digital pathology, molecular tumour boards, AI validation, real-world evidence and health-system readiness.
Europe cannot afford an innovation map where discovery happens in one country, reimbursement in another and access depends on postcode. The EU will not lead in life sciences unless it leads in implementation.
IPM Alliance will carry this message into Dublin’s wider Presidency health-policy week, including a planned Presidency-linked meeting on 2 October.
Europe’s real test is no longer whether it can invent the future of medicine. It is whether patients can use it.
The World’s Lowest Price Has a Catch
Trump’s pricing push is winning big-company signatures. Smaller pharma is not rushing to the table. Reuters reports that 17 major drugmakers have agreed to most-favoured-nation pricing arrangements. But among 19 of the next-largest companies contacted, only Astellas confirmed that it had applied to the related Medicaid pilot. Mid-sized companies argue that international-reference pricing hits differently when a business has fewer products, smaller margins and greater dependence on licensing income. Reuters | White House MFN policy summary.
The United States needs a serious answer to drug prices. But access policy cannot end at the invoice. The question is what happens to launches, trials and investment when the companies carrying specialised, rare-disease and high-risk assets decide the market no longer works for them. Lower prices matter. So does keeping the next generation of medicines alive.
Britain Cut the Bill. The Access Tab Is Still Open.
Britain has made the market less punitive. Patients are still waiting to see whether it becomes more accessible. From 1 July, the UK statutory payment rate for newer branded medicines falls to 16.5%. Because companies paid 24.3% in the first half of 2026, the rate for the rest of the year is 8.7%, designed to produce a full-year average of 16.5%. Industry respondents warned that higher rates could deter investment, disrupt supply and delay launches. UK Department of Health and Social Care response.
That is a sensible correction. But a lower payment rate is not an access strategy. Patients do not experience commercial equivalence. They experience the time between approval, assessment, diagnostics, commissioning and treatment. Britain has eased one pressure point. The real test is whether the NHS can now turn a more credible market into faster access.
The price of the pathway
GLP-1s Just Took the Side Door to Medicare
Medicare has created a route to obesity treatment without rebuilding the benefit system around it. From 1 July, the Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to certain GLP-1 medicines through a CMS demonstration running until 31 December 2027. The programme operates outside the usual Part D coverage and payment flow. Eligible patients pay a $50 co-pay, but the Part D deductible does not apply, the payment does not count towards ordinary out-of-pocket thresholds and low-income subsidies do not apply. CMS Medicare GLP-1 Bridge.
It is a meaningful access signal, but it is also a workaround. Obesity is not a short-term condition, and chronic therapies do not become sustainable because a pilot creates a temporary route around the benefit design. A bridge can help patients cross today. It is not the same as building the road.
COVID’s Emergency Exit Is Open
HHS has terminated the COVID-19 emergency-use-authorisation declarations for drugs, biologics and devices. The change is phased: declarations for drugs and biologics end after 12 months, while device declarations end after 180 days. HHS says the transition reflects the availability of products through traditional approval, clearance and licensing routes. HHS announcement.
This is not only administrative housekeeping. Emergency authorisation was a delivery model: faster decisions, procurement at speed and a willingness to act under uncertainty. Innovation cannot live forever on emergency powers. But the return to normal cannot become an excuse for normal delays. The real question is whether the regular system can move quickly enough when the next crisis arrives.
The Cure Just Got a Bodyguard
For some blood-cancer patients, the transplant can become part of the harm. FDA has approved a therapy designed to reduce that risk. FDA approved Tregzi, the first regulatory T-cell-based immunotherapy intended to improve chronic graft-versus-host-disease-free survival in adults with blood cancers undergoing allogeneic stem-cell transplantation. In the 187-patient PRECISION-T trial, 78% of people receiving Tregzi achieved that outcome at one year, compared with 38.4% receiving standard transplantation. FDA approval announcement.
This is more than another oncology approval. It is personalised medicine becoming more intelligent about the treatment pathway itself: not only attacking the disease, but protecting the patient from the cure. Now comes the hard part: specialist centres, referral capacity, manufacturing reliability and reimbursement built for complex cellular therapy.
The Resistance Crisis Is Growing in the Dark
The next resistance crisis may not arrive with a new superbug. It may arrive with a fungus the system never built the capacity to detect. WHO’s new blueprint on fungal disease and antifungal resistance warns that fungal diseases affect more than 300 million people every year, yet remain largely absent from national health plans, AMR strategies, surveillance systems and universal-health-coverage planning. It calls for stronger diagnostics, laboratory networks, stewardship, surveillance and access to quality-assured antifungals. WHO Blueprint | WHO announcement.
This is not a niche problem for microbiologists. It is an access problem for people with cancer, HIV, transplants and compromised immunity, the people least able to absorb diagnostic delay or ineffective treatment. You cannot personalise treatment for an infection you cannot diagnose, track or afford to treat.
The First-Week-of-July Watch
| 1 July, EU: |
| Ireland takes over the Council of the EU Presidency, with biotechnology, medical devices and competitiveness now firmly on the political agenda. |
| 1–2 July, Amsterdam and online: |
| EMA’s cardiovascular innovation workshop brings medicines, devices, AI and real-world data into the same conversation. |
| 2 July, Amsterdam: |
| EMA hosts its industry platform on research and development support. Watch the regulatory tools before they become routine. |
| 6–9 July, Amsterdam: |
| EMA’s PRAC safety committee meets. The gate does not close after approval. |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
This email was sent to jayasinghtec29@gmail.com. You are receiving this email because you are part of the IPM Alliance network or have engaged with our activities, briefings, events, or policy work.
